TN2009000084A1 - Adenosine derivatives as a2a receptor agonists - Google Patents

Adenosine derivatives as a2a receptor agonists

Info

Publication number: TN2009000084A1
Authority: TN; Tunisia
Prior art keywords: receptor agonists; adenosine derivatives; stereoisomers; compounds; formula
Prior art date: 2006-09-14

Application number

TN2009000084A

Other languages

English (en)

Inventor

Robin Alec Fairhurst

Roger John Taylor

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-14

Filing date

2009-03-13

Publication date

2010-08-19

2009-03-13 Application filed by Novartis Ag filed Critical Novartis Ag

2010-08-19 Publication of TN2009000084A1 publication Critical patent/TN2009000084A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Hydrogenated Pyridines (AREA)

TN2009000084A 2006-09-14 2009-03-13 Adenosine derivatives as a2a receptor agonists TN2009000084A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06120706A EP1903044A1 (fr)	2006-09-14	2006-09-14	Derivés de l'adénosine en tant qu' agonistes du récepteur A2A
PCT/EP2007/059666 WO2008031875A1 (fr)	2006-09-14	2007-09-13	Utilisation de dérivés de l'adénosine en tant qu'agonistes du récepteurs a2a

Publications (1)

Publication Number	Publication Date
TN2009000084A1 true TN2009000084A1 (en)	2010-08-19

Family

ID=37622170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2009000084A TN2009000084A1 (en)	2006-09-14	2009-03-13	Adenosine derivatives as a2a receptor agonists

Country Status (30)

Country	Link
US (1)	US8188100B2 (fr)
EP (2)	EP1903044A1 (fr)
JP (1)	JP2010503639A (fr)
KR (1)	KR20090040386A (fr)
CN (1)	CN101511831B (fr)
AR (1)	AR062768A1 (fr)
AT (1)	ATE481404T1 (fr)
AU (1)	AU2007296227A1 (fr)
BR (1)	BRPI0716936A2 (fr)
CA (1)	CA2662104A1 (fr)
CL (1)	CL2007002658A1 (fr)
CR (1)	CR10621A (fr)
CY (1)	CY1110990T1 (fr)
DE (1)	DE602007009272D1 (fr)
DK (1)	DK2066669T3 (fr)
ES (1)	ES2353141T3 (fr)
HR (1)	HRP20100694T1 (fr)
IL (1)	IL197153A0 (fr)
MA (1)	MA30722B1 (fr)
MX (1)	MX2009002811A (fr)
NO (1)	NO20091244L (fr)
PE (1)	PE20081151A1 (fr)
PL (1)	PL2066669T3 (fr)
PT (1)	PT2066669E (fr)
RU (1)	RU2009113668A (fr)
SI (1)	SI2066669T1 (fr)
TN (1)	TN2009000084A1 (fr)
TW (1)	TW200821324A (fr)
WO (1)	WO2008031875A1 (fr)
ZA (1)	ZA200901036B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ532062A (en) *	2001-10-01	2006-09-29	Univ Virginia	2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
GT200500281A (es) *	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
JP2008520744A (ja)	2004-11-19	2008-06-19	ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア	抗炎症性ピラゾロピリミジン
GB0500785D0 (en)	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
WO2007120972A2 (fr) *	2006-02-10	2007-10-25	University Of Virginia Patent Foundation	Procede permettant de traiter l'anemie a hematies falciformes
AU2007347115A1 (en)	2006-04-04	2008-10-23	The Regents Of The University Of California	PI3 kinase antagonists
GB0607944D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607953D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607950D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
HRP20120494T1 (hr)	2006-04-21	2012-08-31	Novartis Ag	Derivati purina za uporabu kao agonista adenozin a2a receptora
US8188063B2 (en)	2006-06-19	2012-05-29	University Of Virginia Patent Foundation	Use of adenosine A2A modulators to treat spinal cord injury
AU2007263726A1 (en) *	2006-06-27	2008-01-03	Biovitrum Ab (Publ)	Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
EP1889846A1 (fr)	2006-07-13	2008-02-20	Novartis AG	Dérivés de purine comme agonistes du recepteur A2a
CA2669108A1 (fr) *	2006-11-10	2008-05-15	Novartis Ag	Derives de monoacetate de cyclopentene diol
GB2467670B (en)	2007-10-04	2012-08-01	Intellikine Inc	Chemical entities and therapeutic uses thereof
CA2703039A1 (fr) *	2007-10-17	2009-04-23	Novartis Ag	Derives de purine comme ligands des recepteurs a1 a l'adenosine
US8058259B2 (en)	2007-12-20	2011-11-15	University Of Virginia Patent Foundation	Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2240451T3 (da)	2008-01-04	2017-11-20	Intellikine Llc	Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
US8637542B2 (en)	2008-03-14	2014-01-28	Intellikine, Inc.	Kinase inhibitors and methods of use
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt)	2008-07-08	2018-06-12	Intellikine Inc	compostos inibidores de quinase e métodos de uso
CA2738429C (fr)	2008-09-26	2016-10-25	Intellikine, Inc.	Inhibiteurs heterocycliques de kinases
CA2740885C (fr)	2008-10-16	2018-04-03	The Regents Of The University Of California	Inhibiteurs d'heteroarylkinase a noyau fusionne
US8476282B2 (en)	2008-11-03	2013-07-02	Intellikine Llc	Benzoxazole kinase inhibitors and methods of use
EP2427195B1 (fr)	2009-05-07	2019-05-01	Intellikine, LLC	Composés hétérocycliques et leurs utilisations
CN102573846B (zh)	2009-08-17	2015-10-07	因特利凯公司	杂环化合物及其用途
WO2011047384A2 (fr)	2009-10-16	2011-04-21	The Regents Of The University Of California	Procédés d'inhibition de l'activité ire1
AU2011255218B2 (en)	2010-05-21	2015-03-12	Infinity Pharmaceuticals, Inc.	Chemical compounds, compositions and methods for kinase modulation
AU2011326427B2 (en)	2010-11-10	2016-01-07	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
PE20180318A1 (es)	2011-01-10	2018-02-09	Infinity Pharmaceuticals Inc	Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
JP6130305B2 (ja)	2011-02-23	2017-05-17	インテリカイン，エルエルシー	キナーゼ阻害剤の組み合わせおよびそれらの使用
WO2013012918A1 (fr)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Composés hétérocycliques et leurs utilisations
WO2013012915A1 (fr)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Composés hétérocycliques et leurs utilisations
AR091790A1 (es)	2011-08-29	2015-03-04	Infinity Pharmaceuticals Inc	Derivados de isoquinolin-1-ona y sus usos
JP6342805B2 (ja)	2011-09-02	2018-06-13	ザリージェンツオブザユニバーシティオブカリフォルニア	置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
KR20150061651A (ko)	2012-09-26	2015-06-04	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	Ire1의 조절
LT2914296T (lt)	2012-11-01	2018-09-25	Infinity Pharmaceuticals, Inc.	Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2015051244A1 (fr)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
EP3119397B1 (fr)	2014-03-19	2022-03-09	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques destinés à être utilisés dans le traitement de troubles médiés par pi3k-gamma
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
CN105012318B (zh) *	2014-04-17	2020-02-11	沈华浩	磺酰胺类化合物在气道慢性炎症性疾病中的应用
WO2016054491A1 (fr)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
CN114230571B (zh)	2015-09-14	2025-07-08	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
BR112018068703B1 (pt)	2016-03-16	2024-02-06	Kura Oncology, Inc.	Inibidores substituídos de menin-mll e métodos de uso
KR102419524B1 (ko) *	2016-03-16	2022-07-08	쿠라 온콜로지, 인크.	메닌-mll의 가교된 이환식 억제제 및 사용 방법
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
UA125216C2 (uk)	2016-06-24	2022-02-02	Інфініті Фармасьютікалз, Інк.	Комбінована терапія
CN117298275A (zh)	2017-03-24	2023-12-29	库拉肿瘤学公司	治疗血液系统恶性肿瘤和尤因肉瘤的方法
WO2018226976A1 (fr)	2017-06-08	2018-12-13	Kura Oncology, Inc.	Procédés et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
TW201920170A (zh)	2017-09-20	2019-06-01	美商庫拉腫瘤技術股份有限公司	經取代之menin-mll 抑制劑及使用方法
CA3077267C (fr)	2017-09-28	2021-02-16	Cstone Pharmaceuticals (Suzhou) Co., Ltd.	Derives a cycles heteroaryles condenses utiles en tant qu'inhibiteur du recepteur a2a
CN113194752A (zh)	2018-06-01	2021-07-30	康奈尔大学	Pi3k相关疾病或病症的组合疗法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1528382A (en) *	1974-12-26	1978-10-11	Teijin Ltd	Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) *	1985-11-06	1988-04-19	Warner-Lambert Company	Novel N6 -substituted-5'-oxidized adenosine analogs
US4873360A (en) *	1986-07-10	1989-10-10	Board Of Governors Of Wayne State University	Process for the preparation of cyclopentanoids and novel intermediates produced thereby
IL84414A0 (en)	1986-11-14	1988-04-29	Ciba Geigy Ag	N9-cyclopentyl-substituted adenine derivatives
US4954504A (en) *	1986-11-14	1990-09-04	Ciba-Geigy Corporation	N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
JP2586897B2 (ja)	1987-03-09	1997-03-05	富士薬品工業株式会社	光学活性なシス−シクロペンテン−３，５−ジオ−ルモノエステルの製造法
CA2092305C (fr)	1990-09-25	2003-02-11	Alfred P. Spada	Composes antihypertenseurs et anti-ischemiques
IT1254915B (it)	1992-04-24	1995-10-11	Gloria Cristalli	Derivati di adenosina ad attivita' a2 agonista
US5688774A (en) *	1993-07-13	1997-11-18	The United States Of America As Represented By The Department Of Health And Human Services	A3 adenosine receptor agonists
US5691188A (en) *	1994-02-14	1997-11-25	American Cyanamid Company	Transformed yeast cells expressing heterologous G-protein coupled receptor
ATE219767T1 (de) *	1996-01-02	2002-07-15	Aventis Pharm Prod Inc	Verfahren zur herstellung von 2,4-dihydroxy- pyridin und 2,4-dihydroxy-3-nitropyridin
US6376472B1 (en) *	1996-07-08	2002-04-23	Aventis Pharmaceuticals, Inc.	Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
CA2289731A1 (fr) *	1997-05-09	1998-11-12	The United States Of America, Represented By The Secretary, Department O F Health And Human Services	Methodes visant a reduire une lesion ischemique cardiaque par administration d'agonistes et d'antagonistes du recepteur d'adenosine et compositions afferentes
GB9813535D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
DE69910213T2 (de)	1998-06-23	2004-07-01	Glaxo Group Ltd., Greenford	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate
GB9813540D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
GB9813554D0 (en) *	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
ATE331726T1 (de)	1998-10-16	2006-07-15	Pfizer	Adenine-derivate
SI1140933T1 (en) *	1998-12-31	2005-02-28	Aventis Pharmaceuticals Inc.	Process for preparing n6-substituted deaza-adenosine derivatives
US7427606B2 (en) *	1999-02-01	2008-09-23	University Of Virginia Patent Foundation	Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en)	1999-06-18	2001-11-27	University Of Virginia Patent Foundation	Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en)	1999-06-22	2002-06-11	Cv Therapeutics, Inc.	N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) *	1999-06-22	2001-04-10	Cv Therapeutics, Inc.	C-pyrazole 2A A receptor agonists
US6586413B2 (en) *	1999-11-05	2003-07-01	The United States Of America As Represented By The Department Of Health And Human Services	Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB0003960D0 (en)	2000-02-18	2000-04-12	Pfizer Ltd	Purine derivatives
GB0022695D0 (en)	2000-09-15	2000-11-01	Pfizer Ltd	Purine Derivatives
AU2002219497B2 (en) *	2001-01-16	2004-08-26	Can-Fite Biopharma Ltd.	Use of an adenosine A3 receptor agonist for inhibition of viral replication
GB2372741A (en)	2001-03-03	2002-09-04	Univ Leiden	C2,8-Disubstituted adenosine derivatives and their different uses
US20040162422A1 (en) *	2001-03-20	2004-08-19	Adrian Hall	Chemical compounds
EP1258247A1 (fr) *	2001-05-14	2002-11-20	Aventis Pharma Deutschland GmbH	Analogues d'adénosine pour le traitement de le diabete et de la resistance à l' insuline
NZ532062A (en)	2001-10-01	2006-09-29	Univ Virginia	2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
US7414036B2 (en) *	2002-01-25	2008-08-19	Muscagen Limited	Compounds useful as A3 adenosine receptor agonists
WO2003086408A1 (fr)	2002-04-10	2003-10-23	University Of Virginia Patent Foundation	Utilisation d'agonistes du recepteur d'adenosine a2a dans le traitement de maladies inflammatoires
EP1699459B1 (fr)	2003-12-29	2007-06-06	Can-Fite Biopharma Ltd.	Methode de traitement de la sclerose en plaques
SG144146A1 (en)	2004-03-05	2008-07-29	Cambridge Biotechnology Ltd	Adenosine receptor agonists
WO2005107463A1 (fr)	2004-05-03	2005-11-17	University Of Virginia Patent Foundation	Agonistes de recepteurs de l'adenosine a2a servant au traitement d'une nephropathie diabetique
PE20060272A1 (es) *	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US7825102B2 (en) *	2004-07-28	2010-11-02	Can-Fite Biopharma Ltd.	Treatment of dry eye conditions
EP1778239B1 (fr)	2004-07-28	2013-08-21	Can-Fite Biopharma Ltd.	Agonistes du recepteur de l'adenosine a3 pour le traitement de troubles de l'oeil sec tels que le syndrome de sjogren
EP1794162A1 (fr) *	2004-09-09	2007-06-13	The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health	Derives de purine comme agonistes du recepteur d'adenosine a3 et a1
GT200500281A (es) *	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
US20080051364A1 (en) *	2004-11-08	2008-02-28	Pninna Fishman	Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en) *	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
SI1848718T1 (sl) *	2005-02-04	2012-12-31	Millennium Pharmaceuticals, Inc.	Inhibitorji E1 aktivacijskih enzimov
GB0505219D0 (en) *	2005-03-14	2005-04-20	Novartis Ag	Organic compounds
GB0514809D0 (en) *	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
EP1959939B1 (fr) *	2005-11-30	2012-01-11	Can-Fite Biopharma Ltd.	Utilisation de l'agoniste des recepteurs de l'adenosine a3 dans le traitement de l'osteoarthrite
DE602007013359D1 (de) *	2006-01-26	2011-05-05	Us Gov Health & Human Serv	Allosterische a3-adenosin-rezeptormodulatoren
JP5231251B2 (ja) *	2006-02-02	2013-07-10	ミレニアムファーマシューティカルズ，インコーポレイテッド	Ｅ１活性化酵素の阻害剤
US20080027022A1 (en) *	2006-02-08	2008-01-31	Linden Joel M	Method to treat gastric lesions
GB0607951D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607953D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607954D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607948D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
HRP20120494T1 (hr) *	2006-04-21	2012-08-31	Novartis Ag	Derivati purina za uporabu kao agonista adenozin a2a receptora
GB0607945D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607950D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607944D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
EP1889846A1 (fr) *	2006-07-13	2008-02-20	Novartis AG	Dérivés de purine comme agonistes du recepteur A2a
US8008307B2 (en) *	2006-08-08	2011-08-30	Millennium Pharmaceuticals, Inc.	Heteroaryl compounds useful as inhibitors of E1 activating enzymes
CA2669108A1 (fr) *	2006-11-10	2008-05-15	Novartis Ag	Derives de monoacetate de cyclopentene diol
US20080312160A1 (en) *	2007-04-09	2008-12-18	Guerrant Richard L	Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en) *	2007-04-23	2008-10-23	Adenosine Therapeutics, Llc	Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
EP2170401A1 (fr) *	2007-06-29	2010-04-07	Government of the United States of America, Represented by the Secretary, Department of Health and Human Services	Conjugués de dendrimère d'agonistes et d'antagonistes de la superfamille des gpcr
US20090181934A1 (en) *	2007-10-17	2009-07-16	Novartis Ag	Organic Compounds
CA2703039A1 (fr) *	2007-10-17	2009-04-23	Novartis Ag	Derives de purine comme ligands des recepteurs a1 a l'adenosine
WO2009061516A1 (fr) *	2007-11-08	2009-05-14	New York University School Of Medicine	Implants médicaux contenant des agonistes du récepteur de l'adénosine et procédés pour inhiber un relâchement d'implant médical
CN101938904A (zh) *	2008-01-09	2011-01-05	PGx健康有限责任公司	用a2ar激动剂鞘内治疗神经性疼痛

2006
- 2006-09-14 EP EP06120706A patent/EP1903044A1/fr not_active Ceased
2007
- 2007-09-12 PE PE2007001224A patent/PE20081151A1/es not_active Application Discontinuation
- 2007-09-12 AR ARP070104040A patent/AR062768A1/es not_active Application Discontinuation
- 2007-09-13 SI SI200730448T patent/SI2066669T1/sl unknown
- 2007-09-13 MX MX2009002811A patent/MX2009002811A/es not_active Application Discontinuation
- 2007-09-13 BR BRPI0716936-1A2A patent/BRPI0716936A2/pt not_active IP Right Cessation
- 2007-09-13 PL PL07803477T patent/PL2066669T3/pl unknown
- 2007-09-13 US US12/310,254 patent/US8188100B2/en not_active Expired - Fee Related
- 2007-09-13 RU RU2009113668/04A patent/RU2009113668A/ru unknown
- 2007-09-13 ES ES07803477T patent/ES2353141T3/es active Active
- 2007-09-13 WO PCT/EP2007/059666 patent/WO2008031875A1/fr not_active Ceased
- 2007-09-13 AT AT07803477T patent/ATE481404T1/de active
- 2007-09-13 CN CN2007800333258A patent/CN101511831B/zh not_active Expired - Fee Related
- 2007-09-13 KR KR1020097005251A patent/KR20090040386A/ko not_active Abandoned
- 2007-09-13 JP JP2009527828A patent/JP2010503639A/ja not_active Withdrawn
- 2007-09-13 AU AU2007296227A patent/AU2007296227A1/en not_active Abandoned
- 2007-09-13 HR HR20100694T patent/HRP20100694T1/hr unknown
- 2007-09-13 CA CA002662104A patent/CA2662104A1/fr not_active Abandoned
- 2007-09-13 TW TW096134289A patent/TW200821324A/zh unknown
- 2007-09-13 PT PT07803477T patent/PT2066669E/pt unknown
- 2007-09-13 DK DK07803477.4T patent/DK2066669T3/da active
- 2007-09-13 CL CL200702658A patent/CL2007002658A1/es unknown
- 2007-09-13 DE DE602007009272T patent/DE602007009272D1/de active Active
- 2007-09-13 EP EP07803477A patent/EP2066669B1/fr active Active
2009
- 2009-02-13 ZA ZA200901036A patent/ZA200901036B/xx unknown
- 2009-02-19 IL IL197153A patent/IL197153A0/en unknown
- 2009-02-19 CR CR10621A patent/CR10621A/es not_active Application Discontinuation
- 2009-03-13 TN TN2009000084A patent/TN2009000084A1/fr unknown
- 2009-03-25 NO NO20091244A patent/NO20091244L/no not_active Application Discontinuation
- 2009-03-30 MA MA31736A patent/MA30722B1/fr unknown
2010
- 2010-12-15 CY CY20101101154T patent/CY1110990T1/el unknown

Also Published As

Publication number	Publication date
EP2066669B1 (fr)	2010-09-15
CL2007002658A1 (es)	2008-08-08
NO20091244L (no)	2009-04-07
CY1110990T1 (el)	2015-06-11
DE602007009272D1 (de)	2010-10-28
RU2009113668A (ru)	2010-10-20
PE20081151A1 (es)	2008-10-06
CR10621A (es)	2009-03-27
MA30722B1 (fr)	2009-09-01
DK2066669T3 (da)	2011-01-10
IL197153A0 (en)	2009-11-18
JP2010503639A (ja)	2010-02-04
EP1903044A1 (fr)	2008-03-26
ZA200901036B (en)	2010-01-27
KR20090040386A (ko)	2009-04-23
WO2008031875A1 (fr)	2008-03-20
US8188100B2 (en)	2012-05-29
ES2353141T3 (es)	2011-02-25
US20090325967A1 (en)	2009-12-31
AR062768A1 (es)	2008-12-03
PT2066669E (pt)	2010-12-17
CA2662104A1 (fr)	2008-03-20
MX2009002811A (es)	2009-03-31
HRP20100694T1 (hr)	2011-01-31
ATE481404T1 (de)	2010-10-15
TW200821324A (en)	2008-05-16
CN101511831A (zh)	2009-08-19
BRPI0716936A2 (pt)	2013-09-17
HK1131392A1 (en)	2010-01-22
SI2066669T1 (sl)	2011-01-31
PL2066669T3 (pl)	2011-03-31
EP2066669A1 (fr)	2009-06-10
AU2007296227A1 (en)	2008-03-20
CN101511831B (zh)	2012-04-25

Publication	Publication Date	Title
TN2009000084A1 (en)	2010-08-19	Adenosine derivatives as a2a receptor agonists
TNSN07268A1 (en)	2008-12-31	Purine derivatives acting as a2a receptor agonists
TNSN08544A1 (en)	2010-04-14	Purine derivatives as a2a agonists
MY146645A (en)	2012-09-14	Purine derivatives for use as adenosin a2a receptor agonists
PL2012759T3 (pl)	2010-08-31	Pochodne puryny jako agoniści receptora A2A
TNSN07154A1 (en)	2008-11-21	Purine derivatives for use as adenosin a-2a receptor agonists
WO2007121921A3 (fr)	2008-01-10	Composés organiques
MX2008016134A (es)	2009-01-15	Derivados de fenol para el tratamiento de enfermedades respiratorias.
TN2010000167A1 (en)	2011-11-11	Organic compounds
NO20072371L (no)	2007-07-12	Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
GEP20105074B (en)	2010-09-10	Pyrimidinyl aryl urea derivatives being fgf inhibitors
TW200738729A (en)	2007-10-16	Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MX2009011802A (es)	2009-11-18	Imidazoquinolinas con propiedades inmunomoduladoras.
MX2009000169A (es)	2009-01-26	Derivados de purinona como agonistas de hm74a.
AU2015221439B2 (en)	2016-07-14	Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
PH12012501800A1 (en)	2012-12-10	2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
WO2007121918A3 (fr)	2008-04-10	Composés organiques
NO20092058L (no)	2009-09-17	Heteroaryl pyrrolidinyl ketonderivater
MX2009003739A (es)	2009-09-04	Derivados de hidrobenzamida como inhibidores de hsp90.
WO2006015860A3 (fr)	2006-06-15	Composes organiques
TNSN08369A1 (en)	2009-12-29	Benzimidazole derivatives
ATE490958T1 (de)	2010-12-15	Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
MY156955A (en)	2016-04-15	Antifungal agents
NO20090421L (no)	2009-02-06	Arylpiperazinderivater og deres anvendelse
MX2010008778A (es)	2010-08-30	Derivados de 3-alquil-piperazina y usos de la misma.